Early Postoperative L-arginine and Acute Kidney Injury After Cardiac Surgery
ConditionAcute Kidney Injury
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorXijing Hospital
About this trial
Acute kidney injury (AKI) is common after cardiac surgery, yet effective protective strategies remain limited. L-arginine is the substrate for endogenous nitric oxide (NO) synthesis and may improve renal perfusion and endothelial function. investigators emulated a target trial to evaluate whether early perioperative L-arginine was associated with a lower risk of AKI after cardiac surgery.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
None
Disqualifiers
congenital heart disease,
surgery requiring deep hypothermic circulatory arrest,
a preoperative baseline estimated glomerular filtration rate (eGFR) below 30 mL/min/1.73 m²,
AKI already present prior to ICU admission
Trial population
adults admitted to the ICU after CPB-assisted cardiac surgery
Trial design
Design model
Cohort
Time perspective
Retrospective
Treatments tested in this trial
L-arginine
DrugInitiation of L-arginine within 3 postoperative days
Treatment groups
5,000 Participants
are divided into 2 treatment groupsGroup A: L-arginine1 intervention
Group B: No L-arginine0 interventions
Trial outcomes
Primary outcomes
1
Acute kidney injury
defined by KDIGO criteria
Time frame
within 7 postoperative daysSecondary outcomes
1
7-day mortality.
7-day mortality.
Time frame
7 dayLocations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: